MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE).
MAGE-A3 195-203 is a synthetic peptide fragment derived from the melanoma-associated antigen A3 (MAGE-A3), corresponding to amino acid residues 195 through 203. As a member of the MAGE family, this peptide is of significant interest in immunological and oncological research due to its restricted expression profile and immunogenic potential. The sequence represents a well-characterized epitope that is frequently studied in the context of antigen presentation, T cell recognition, and tumor immunology. Researchers utilize this peptide to investigate cellular immune responses, understand tumor antigenicity, and explore mechanisms underlying cancer immunosurveillance. Its defined sequence and relevance to tumor-associated antigens make it a valuable biochemical tool for various experimental applications in immunology, oncology, and peptide-based assay development.
Antigen Presentation Studies: The 195-203 peptide of MAGE-A3 is widely employed to study the mechanisms of antigen processing and presentation via major histocompatibility complex (MHC) class I molecules. By incorporating this peptide into in vitro systems, investigators can examine how antigen-presenting cells process and display tumor-derived epitopes, facilitating the activation of cytotoxic T lymphocytes (CTLs). This application is critical for elucidating the molecular determinants of immune recognition and the factors influencing the immunogenicity of tumor antigens.
T Cell Epitope Mapping: Researchers use the MAGE-A3 195-203 peptide to map T cell epitopes and characterize the specificity of T cell receptors (TCRs) in experimental models. Functional assays involving this peptide enable the identification and quantification of antigen-specific CD8+ T cell populations, providing insights into immune repertoire diversity and the dynamics of T cell-mediated responses against tumor-associated antigens. Such studies contribute to a deeper understanding of adaptive immunity in the context of cancer.
Peptide-Based Immunoassays: The defined sequence and immunological relevance of this peptide make it a preferred reagent in the development and optimization of peptide-based immunoassays. It is frequently utilized as a standard or probe in enzyme-linked immunospot (ELISpot) assays, intracellular cytokine staining, and other immunological assays designed to detect and quantify antigen-specific T cell responses. The use of this peptide in assay development enhances the sensitivity and specificity of immune monitoring platforms.
Vaccine Research Models: In preclinical research, the MAGE-A3 195-203 peptide serves as a model antigen for evaluating peptide vaccine strategies and immune adjuvant formulations. Its ability to elicit defined T cell responses allows scientists to assess the efficacy of novel immunization protocols, delivery systems, and combination therapies in eliciting robust cellular immunity. These studies are instrumental in advancing the field of cancer immunoprevention and immunotherapy research.
Tumor Immunology Mechanism Exploration: The peptide is also employed to dissect the mechanisms of immune evasion and tumor-immune interactions. By integrating this epitope into co-culture systems or adoptive transfer models, researchers can analyze how tumor cells modulate antigen expression, interfere with immune synapse formation, or escape CTL-mediated lysis. Such mechanistic investigations inform the design of targeted interventions to enhance anti-tumor immunity and overcome immune resistance in the tumor microenvironment.
1. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
2. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More